The American Society of Clinical Oncology (ASCO) conference showcased exciting new data for oncology treatments, with several drugs showing significant success rates. AstraZeneca's Tagrisso was found to outperform a placebo in trials for EGFR-mutated non-small cell lung cancer, Novartis' Kisqali impressed researchers with its ability to treat early breast cancer, and Merck's Keytruda was more effective than Astra's Imfinzi in treating perioperative NSCLC. Moderna and Merck also released promising results from their personalized cancer vaccine. The results were described as "practice-changing" by medical professionals attending the conference. ASCO President Lynn Schuchter highlighted research into de-escalation which can reduce toxicity levels.
Keywords: ASCO conference, oncology treatments, Tagrisso, Kisqali, Keytruda
Other related sentences:
- The latest advances in oncology treatments were presented at the 2023 ASCO conference.
- Medical professionals are excited about the potential benefits of personalized cancer vaccines like Moderna and Merck's mRNA-4157.
- De-escalation is an important area of research that could help reduce toxicity levels during treatment.